SynthesisJournal of managed care & specialty pharmacy2021
Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
Synthesis in Journal of managed care & specialty pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Real-world avelumab first-line maintenance in advanced urothelial carcinoma: systematic review and meta-analysis.Future oncology (London, England) · 2025Pooled it
- Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis.Future oncology (London, England) · 2024Pooled it
- HER2 expression in urothelial carcinoma, a systematic literature review.Frontiers in oncology · 2022Pooled it
- Pan-Asian subgroup analysis of EV-302/KEYNOTE-A39: a phase 3 study to evaluate enfortumab vedotin and pembrolizumab in patients with untreated advanced urothelial carcinoma.International journal of clinical oncology · 2026Trial
- Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in China.Cancer medicine · 2024Trial
- Cost-effectiveness of disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial carcinoma in China.Frontiers in pharmacology · 2026Article
- One Man's Meat Is Another Man's Poison: High Incidence of Severe Cutaneous Drug Reactions Induced by Enfortumab Vedotin.European urology open science · 2025Article
- Cost-Effectiveness of Enfortumab Vedotin and Pembrolizumab for First-Line Metastatic Urothelial Cancer in the United States.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2025Article
- COSMIC-021 Phase Ib Study of Cabozantinib Plus Atezolizumab: Results from the Locally Advanced or Metastatic Urothelial Carcinoma Cohorts.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study.Current oncology (Toronto, Ont.) · 2025Article
- Treatment of metastatic urothelial carcinoma in the United Kingdom, France, Germany, Italy, and Spain.Future oncology (London, England) · 2025Article
- Patient Preferences for First-Line Treatment of Locally Advanced or Metastatic Urothelial Carcinoma: An Application of Multidimensional Thresholding.The patient · 2025Article
- Observational
- Development and Optimization of a Bladder Cancer Algorithm Using SEER-Medicare Claims Data.JCO clinical cancer informatics · 2024Article
- Real-world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey.International journal of urology : official journal of the Japanese Urological Association · 2024Article
- Real-world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan.International journal of urology : official journal of the Japanese Urological Association · 2024Article
- Advancements in First-Line Treatment of Metastatic Bladder Cancer: EV-302 and Checkmate-901 Insights and Future Directions.Cancers · 2024Review
- Evaluating Oncologists' Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study.The oncologist · 2024Article
- Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China.Frontiers in pharmacology · 2024Article
- Expression of HER2 in high-grade urothelial carcinoma based on Chinese expert consensus and the clinical effects of disitamab vedotin-tislelizumab combination therapy in the treatment of advanced patients.Frontiers in pharmacology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.